Aerpio Therapeutics Reports Peer-Reviewed Publication of Positive Clinical Results from the Phase 2a Study of Lead Candidate, AKB-9778, in Diabetic Macular Edema (DME): The TIME-2 Trial

CINCINNATI–(BUSINESS WIRE)–Aerpio Therapeutics, Inc., a biopharmaceutical company focused on advancing first-in-class treatments for the eye, today announced that clinical data from the company’s Phase 2a study of its lead candidate, AKB-9778, for the treatment of patients with DME, have been published in an article titled “Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation …